Last reviewed · How we verify
NCT05221645: P+R-ICE
Pembrolizumab in Combination With R-ICE Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma
Phase 2 trial testing Pembrolizumab in Diffuse Large B Cell Lymphoma in 65 participants. Participants enrolled and being followed up; not accepting new ones.
30 May 2026
Quick facts
| Lead sponsor | University of Southampton |
|---|---|
| Phase | Phase 2 |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 65 |
| Start date | 27 June 2022 |
| Primary completion | 30 May 2026 |
| Estimated completion | 31 December 2026 |
| Sites | 2 locations across United Kingdom |
Drugs / interventions tested
- Pembrolizumab (pembrolizumab) — full drug profile →
- Rituximab — full drug profile →
- Ifosfamide
- Carboplatin (Carboplatin) — full drug profile →
- Etoposide (etoposide) — full drug profile →
Conditions studied
- Diffuse Large B Cell Lymphoma — all drugs for Diffuse Large B Cell Lymphoma →
Sponsor
University of Southampton
Who can join
18 and older, any sex, with Diffuse Large B Cell Lymphoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is an open-label, multicentre, randomised phase II trial in relapsed or refractory diffuse large B-cell lymphoma.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Targeting natural killer cells: from basic biology to clinical application in hematologic malignancies.
Shang J, Hu S, Wang X. · · 2024 · cited 13× · PMID 38396050 · DOI 10.1186/s40164-024-00481-y -
Redefining Precision Management of r/r Large B-Cell Lymphoma: Novel Antibodies Take on CART and BMT in the Quest for Future Treatment Strategies.
Dada R. · · 2023 · cited 7× · PMID 37508523 · DOI 10.3390/cells12141858 -
Including patient and public contributors on clinical trial Independent Data Monitoring Committees (IDMCs).
Allaway E, Soulsby I, Keyworth N, Stanton L, et al · · 2026 · PMID 41703579 · DOI 10.1186/s13063-026-09559-w
Verify or expand the search:
- PubMed search for NCT05221645
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Pembrolizumab
Trials testing the same drug.
- NCT07572123 — Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem · Phase 2, PHASE3 · not yet recruiting
- NCT07275216 — Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Stand · Phase 2 · not yet recruiting
- NCT07302347 — A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participan · Phase 1, PHASE2 · recruiting
- NCT06724042 — Study of ISM5939 in Patients With Advanced and/or Metastatic Solid Tumors · Phase 1 · not yet recruiting
- NCT07383441 — Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer · Phase 3 · not yet recruiting
Other recruiting trials for Diffuse Large B Cell Lymphoma
Currently open trials in the same condition.
- NCT06687772 — CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant · Phase 2 · recruiting
- NCT06208735 — CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies · Phase 1 · recruiting
- NCT06736613 — A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma · Phase 2 · recruiting
- NCT06552572 — Glofitamab in Relapsed or Refractory Diffuse Large B-cell Lymphoma After CD19 Chimeric Antigen Receptor T-cell Therapy · Phase 2 · active not recruiting
- NCT06550141 — Emapalumab Prevention of CAR-T Cell Associated Toxicities · Phase 2 · recruiting
Other University of Southampton trials
Trials by the same sponsor.
- NCT07531277 — Developing Resource Interventions for Healthcare Professionals and Patients to Improve Knowledge About Fertility in Prim · NA · not yet recruiting
- NCT06923943 — Predicting Nurse Staffing Requirements From Routinely Collected Data · active not recruiting
- NCT06692959 — A Phase II Trial of Neoadjuvant PD-1 Vaccine PD1-Vaxx in Operable MSI High Colorectal Cancer · Phase 2 · recruiting
- NCT06815120 — A Novel Ureteric Stent in Kidney Stone Patients and Oncology Patients Compared to a Conventional JJ Stent · NA · not yet recruiting
- NCT06566157 — PROMOTE: The Effect of a Six Week Prebiotic Supplementation on Wellbeing of Young Adults. · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05221645 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Southampton
- Last refreshed: 5 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05221645.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing